Puma Biotechnology (PBYI) Current Assets (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Current Assets data on file, last reported at $142.3 million in Q1 2026.

• Quarterly Current Assets rose 7.36% year-over-year to $142.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $142.3 million (up 7.36% YoY) and the FY2025 annual result came in at $162.7 million, up 10.18% from the prior year.
• Current Assets eased to $142.3 million in Q1 2026, from $162.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $162.7 million in Q4 2025 to a low of $111.8 million in Q1 2023.
• A 5-year average of $135.5 million and a median of $136.6 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets tumbled 31.88% — and 2024, when it increased 27.98%.
• Tracing PBYI's Current Assets over 5 years: stood at $134.3 million in 2022, then climbed by 16.31% to $156.2 million in 2023, then dropped by 5.46% to $147.7 million in 2024, then rose by 10.18% to $162.7 million in 2025, then retreated by 12.56% to $142.3 million in 2026.
• The last three Current Assets figures came in at $142.3 million (Q1 2026), $162.7 million (Q4 2025), and $143.6 million (Q3 2025), per Business Quant data.